Podcasts about Moores Cancer Center

Charles Parisi, co-hosting for Drew Schlosberg, joined by Associate Producer Brandon Joe, enjoy a fascinating conversation with two "South County babies" who picked up their golden tickets of education and headed off to great UC universities, ultimately returning to San Diego to serve the public health needs of San Diego  through the UCSD Moores Cancer Center.  Enjoy listening to Maritza Gomez and Dahlia Sandoval tell their powerful and inspiring storiesAbout Spotlight and Cloudcast Media"Spotlight On The Community" is the longest running community podcast in the country, continuously hosted by Drew Schlosberg for 19 years.  "Spotlight" is part of Cloudcast Media's line-up of powerful local podcasts, telling the stories, highlighting the people, and celebrating the gravitational power of local. For more information on Cloudcast and its shows and cities served, please visit www.cloudcastmedia.us.Cloudcast Media | the national leader in local podcasting.  About Mission Fed Credit UnionA community champion for over 60 years, Mission Fed Credit Union with over $6 billion in member assets, is the Sponsor of Spotlight On The Community, helping to curate connectivity, collaboration, and catalytic conversations.  For more information on the many services for San Diego residents, be sure to visit them at https://www.missionfed.com/

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here. (https://www.researchtopractice.com/PostASCO2024/RCC)

Starting April 1, 2024, Diane M. Simeone, MD will start her new position as director of the University of California San Diego (UCSD) Health Moores Cancer Center.1  In a conversation with CancerNetwork®, Simeone highlighted her excitement to be working with an institution that she said aligns with her goals and values. During her time as director, she said that she wants to focus more on early detection of pancreatic cancer, which may help save many patients. Additionally, some of her short- and long-term goals include submitting a Cancer Center Support Grant to the National Institutes of Health and expanding clinical trial efforts at UCSD. She also discussed ongoing projects she will aim to work on, such as the UC Pancreatic Cancer (UCPCC) Consortium and the Pancreatic Cancer Early Detection (PRECEDE) Consortium.2,3 Prior to beginning her new position at UCSD, Simeone has been the Laura and Isaac Perlmutter Professor of Surgery, director of the Pancreatic Cancer Center, and the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. Additionally, she was previously the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and a member of the scientific advisory board for the Let's Win Pancreatic Cancer online community.  “It was clear that everybody is aligned with this mission and understands the importance of how we care for patients with cancer and do research at the cancer center,” Simeone said during the interview. “There seems to be a clear commonality of thinking on their vision of being at the forefront of advancing science and, most importantly, how we apply to take care of patients. Patients are always the driving force. That's always the center of what we need to be thinking about.” References 1.     World-renowned surgeon named new director of Moores Cancer Center at UC San Diego Health. News release. University of California San Diego. January 8, 2024. Accessed January 25, 2024. http://tinyurl.com/4986f4cb 2.     UC Pancreatic Cancer Consortium. University of California Health. Accessed January 25, 2024. http://tinyurl.com/3szdvyxv 3.     PanCAN's Precision Promise adaptive clinical trial platform –. Pancreatic Cancer Action Network. Published April 27, 2016. Accessed January 25, 2024. http://tinyurl.com/fpax5hhd

In 2021 Chase's wife Keri was diagnosed with with a life altering illness that would change the course of theirs and their kids lives. Today's episode Burner and Felipe talk to Chase about Keri's journey from that day through her treatments and beyond. This very honest and difficult story is one of love, community, friendships and most of all family.Support the show

Dave Mason, our guest Host, and co-Host, Shiva Kabra, a high school student, have a fantastic conversation with Karina Moyano, the Director of Community Outreach & Engagement, and Margaux Stack-Babich, the Community Outreach & Engagement Coordinator, for the UCSD Moores Cancer Center. As the only NCI cancer center in San Diego, the Moores Cancer Center conducts life changing research, world class treatment, and high impact community engagement to promote cancer prevention. Karina and Margaux share with listeners an overview of their various community programs as well as what they love most about their careers. Thank you for listening to Spotlight On The Community - the #1, longest running community podcast in American history.

Margaux Stack-Babich, MPH and Karina Moyano, MPH, Community Outreach and Engagement Manager UCSD Moores Cancer Center, join the podcast to talk about working alongside Dr. Calac on SD PATH (San Diego Protecting AgainsT HPV). There is so much to learn about HPV, the effectiveness of the HPV vaccine, and how HPV affects the native communities in a harder way, and some positive local news regarding HPV in today's episode. Learn more at the SD PATH site: https://moorescancercenter.ucsd.edu/outreach/hpv-vaccination-workgroup.html --- Send in a voice message: https://anchor.fm/ihcwhataboutlife/message

Most human diseases are localised in terms of their location but currently, injected or orally administered drugs are evenly distributed all over the body and thus, act indiscriminately. The targeted delivery of medication to the exact site where it is needed is a common theme in science fiction but thanks to Professor Richard Klemke and his team at the University of California San Diego's Moores Cancer Center, this fantasy may soon become a reality.

Carole Baggerly is Founding Director of GrassrootsHealth, a 501c3 non-profit public health promotion organization, with the direction of ‘Moving Research into Practice'. She is the leader of the D*action project, an international project co-designed by Dr. Cedric F. Garland of UCSD's School of Medicine and member of Moores Cancer Center. This organization's mission is to move research into practice-NOW—to help move the population into an orientation of health and prevention vs fixing an illness. GrassrootsHealth has introduced new methodologies of Field Trials, with testing and education to get valid ‘real-world' information about how nutrients actually perform, and, how to move beyond the limitations of randomized controlled trials. The organization is guided by a panel of 48 of the world's leading researchers in vitamin D and now, other nutrient researchers. The key implementation innovation in this project is the use of the ‘Field Trial', a formalized methodology, approved by an institution review board, used by participating individuals. The group has initiated the ‘Nutrient Research Institute' to enable testing and analysis of many nutrients together—to see how they work with each other, which they do. More information on GrassRootsHealth Twitter Grassroot4VitD  Instagram @Grassrootshealth Facebook @GrassrootsHealth    

Dr Ezra Cohen from the Moores Cancer Center at UC San Diego Health in La Jolla, California, discusses key abstracts presented in head, neck and thyroid cancers at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOHN22).

The inflating price tag of cancer care means that more patients are facing the difficult choice of paying for everyday needs or their cancer treatment. Matthew Banegas, PhD, MPH, MS, associate professor of radiation medicine and applied sciences at the University of California San Diego and a member of Moores Cancer Center's Cancer Control Program, talks with Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, about COVID-driven financial hardship and its implications for cancer care. Banegas presented about the topic at the 47th Annual ONS Congress in Anaheim, CA, on April 30, 2022; his session is linked in the episode notes. You can also earn free NCPD contact hours by completing the evaluation linked in the episode notes.    Music Credit: "Fireflies and Stardust" by Kevin MacLeod   Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 29, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Episode Notes  Check out these resources from today's episode:  Complete this evaluation for free NCPD.  Learn more about Banegas's ONS Congress session and watch it on demand from May 23–June 30, 2022.   Oncology Nursing Podcast episodes about financial hardship and cost of care  ONS Voice articles about financial hardship and advocacy  Clinical Journal of Oncology Nursing article about financial navigation  HealthCare.gov's glossary of health insurance terminology  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. 

Kelly speaks to Trey Ideker, a professor at UC San Diego School of Medicine and Moores Cancer Center. 

The team traveled to Moore's Cancer Center at UCSD to record this special episode.  Dr. Millard was a great source of information for all things cancer and you can learn more about him below.Learn more about the podcast & follow our story - deathwithdignitypodcast.com // @DWDPodcast2021 (Twitter) About Frederick Millard, MDFrederick Millard, MD, is a board-certified medical oncologist who specializes in treating people with genitourinary (urologic) cancers, including bladder cancer, kidney cancer, prostate cancer, testicular cancer and other germ cell tumors, as well as other rarer cancer types.He is a founder and former co-director of the genitourinary oncology team at UC San Diego Health's Moores Cancer Center. His particular interest is in treatment of patients with germ cell tumors (testicular cancer) and improving the care of these patients in the San Diego community.Dr. Millard also participates in the clinical research effort for patients with these illnesses, conducting clinical trials to help find new ways to improve treatments and the quality of life for people with urologic cancer. He is part of the only oncology clinical research program dedicated solely to urological cancers in the San Diego area.As a professor in the Department of Medicine, Dr. Millard instructs medical students, residents, and fellows at UC San Diego School of Medicine. His work has appeared in many peer-reviewed publications, including Urologic Oncology, Clinical Cancer Research and the Clinical Genitourinary Cancer.Dr. Millard completed a fellowship in hematology/oncology, and a residency in internal medicine at the Naval Medical Center in San Diego. He earned his medical degree from Sidney Kimmel Medical College in Philadelphia.He is board certified in medical oncology, hematology and internal medicine, and is a member of the American Society of Clinical Oncology.

Scott Lippman, MD Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD, Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD, Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD, Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD, Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

Scott Lippman, MD, Ludmil Alexandrov, PhD, and Hannah Carter, PhD discuss the genetic, lifestyle-related, and environmental risk factors identified in cancer prevention. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 37281]

SHR # 2662:: When, not What You Eat May Reduce Breast Cancer Risk PLUS One Listener's Experience With The Carnivore Diet - Guest: Nicholas Webster, Ph.D. M.A - Mike Hazel - Part 1 - Intermittent fasting aligned with circadian rhythms improved insulin levels and reduced tumor growth. Restricting eating to an eight-hour window, when activity is highest, decreased the risk of development, growth and metastasis of breast cancer in mouse models, report researchers at University of California San Diego School of Medicine, Moores Cancer Center and Veterans Affairs San Diego Healthcare System (VASDSH). The findings, published in the January 25, 2021 edition of Nature Communications, show that time-restricted feeding -- a form of intermittent fasting aligned with circadian rhythms -- improved metabolic health and tumor circadian rhythms in mice with obesity-driven postmenopausal breast cancer. with Nicholas Webster, Ph.D. M.A - Source: https://www.nature.com/articles/s41467-020-20743-7 . Part 2 - One man's journey to find a diet that improved his health and energy levels long term lead to an N=1 experiment. He went from Vegan to Keto to Carnivore. Each diet provided different benefits and drawbacks. His findings and results will surely surprise you. with Mike Hazel

SHR # 2662:: When, not What You Eat May Reduce Breast Cancer Risk PLUS One Listener's Experience With The Carnivore Diet - Guest: Nicholas Webster, Ph.D. M.A - Mike Hazel - Part 1 - Intermittent fasting aligned with circadian rhythms improved insulin levels and reduced tumor growth. Restricting eating to an eight-hour window, when activity is highest, decreased the risk of development, growth and metastasis of breast cancer in mouse models, report researchers at University of California San Diego School of Medicine, Moores Cancer Center and Veterans Affairs San Diego Healthcare System (VASDSH). The findings, published in the January 25, 2021 edition of Nature Communications, show that time-restricted feeding -- a form of intermittent fasting aligned with circadian rhythms -- improved metabolic health and tumor circadian rhythms in mice with obesity-driven postmenopausal breast cancer. with Nicholas Webster, Ph.D. M.A - Source: https://www.nature.com/articles/s41467-020-20743-7 . Part 2 - One man's journey to find a diet that improved his health and energy levels long term lead to an N=1 experiment. He went from Vegan to Keto to Carnivore. Each diet provided different benefits and drawbacks. His findings and results will surely surprise you. with Mike Hazel

Christina Jordan, Executive Director of the Immunotherapy Foundation, is joined by Dr. Ezra Cohen M.D., Medical Oncologist and Associate Director of Translational Science at Moores Cancer Center, to detail promising cancer treatment methods. Jordan talks about the foundation's $6 million fundraising campaign and its Help Our Cancer Heroes campaign, which provided meals and PPE to nurses and doctors. Dr. Cohen explains the process of immune system activation for treating cancer and highlights the Tumor Infiltrating Lymphocyte clinical trials taking place at UCSD.

Joel T Nowak from Cancer ABCs discusses with Dr. Rana McKay, Associate Professor of Medicine at the Moores Cancer Center at the University of California in San Diego, her recently published article that analysizes real world data that demonstrates that Provenge (sipuleucel-T), an immune therapy for castrate resistant metastatic prostate cancer (CRMPC), can reduce the risk of death over and above the newer hormone treatments that have been FDA approved . Dr, McKay evaluated a large medicare data base and determined that despite the addition of the many second generation hormone treatments like Zytiga, Xtandi and Nubequa Provenge continues to lower the risk of death for men with CRMPC. She also discussed research that she has ben involved in that has been evaluating survival risks for men with prostate cancer who get the COVID-19 virus. Support the show (https://www.cancerabcs.org/new-page-2/)

Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient outcomes and quality of life. Plus, it’s enrollment season! Get the information you need for Medicare enrollment in this week’s conversation with Samantha Smith from the Patients Rising Concierge. And as November marks Lung Cancer Awareness Month, Terry and Dr. Bob look at COVID-19’s impact on cancer screenings and late-stage diagnoses. Guest:Razelle Kurzrock, M.D.Chief Medical Advisor and Co-Founder, CureMatchA board-certified medical oncologist and a renowned expert in precision medicine, Dr. Kurzrock is known for developing one of the largest and best known Phase I clinical trial programs in the United States while at MD Anderson Cancer Center in Texas. She is currently heading UCSD’s newly established Center for Personalized Cancer Therapy at the Moores Cancer Center in San Diego, California.As a physician-scientist, she brings extraordinary expertise, clinical research insights, and business operations experience, while also serving as Chief of the Hematology and Oncology Division at the UCSD School of Medicine. With over 400 peer-reviewed published articles, she has a strong record of competitive grant funding. She also has been the principal investigator for the National Cancer Institute’s U01 Phase I Studies of Targeted Anti-Cancer Agents. Dr. Kurzrock received her medical degree from the University of Toronto School of Medicine. Hosts:Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.Kate Pecora, Field Correspondent Links:Dr. Razelle KurzrockCureMatchSamantha SmithG-PactHow AI is helping lung cancer patientsCOVID-19 in cancer patients on systemic anti-cancer therapiesModerna’s COVID-19 Vaccine: What You Need to KnowPatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

Discover the latest innovations in comprehensive breast health care from experts at UC San Diego Health and Moores Cancer Center. Anne Wallace, MD, Rebecca Shatsky, MD, and Mohammad Eghtedari, MD, PhD discuss the team approach to breast cancer detection, treatment and prevention utilizing breast imaging, medical, surgical and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36458]

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, attendees from 138 countries worldwide gathered virtually for the ASCO20 Virtual Scientific Program, held Friday, May 29 through Sunday, May 31. In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?” In this episode, editors discuss new research in the fields of head and neck cancer and melanoma. First, Dr. Ezra Cohen will discuss new research in squamous cell carcinoma of the head and neck and adenoid cystic carcinoma. Dr. Cohen is Co-Director of the San Diego Center for Precision Immunotherapy, Associate Director of Translational Science and leads the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. He is also the Cancer.Net Associate Editor for Head and Neck Cancers. View Dr. Cohen’s disclosures at Cancer.Net. Dr. Cohen: Hi. This is Dr. Ezra Cohen from University of California, San Diego, Moores Cancer Center. And today I'll be reviewing head/neck cancer abstracts from the American Society of Clinical Oncology Annual Meeting. I have consulted for Merck in the past. As all of us know, this meeting was virtual this year, but we had an opportunity to see the broadcasts through the virtual website. And there were a few abstracts that I thought were relevant to not only current standards of care but also to the future of research in head/neck cancer. The first one I'll talk about is a Japanese study that compared post-operative chemo radiotherapy of 3 weekly cisplatin versus weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck. This was indeed an adjuvant trial or a post-operative trial, and really addressed an important question in the field that had been controversial and perhaps continues to be going forward. The investigators compared a dose of 40 milligrams per meter squared given every week versus the standard 100 milligram per meter squared of cisplatin given every three weeks and assess patients for local-regional control and overall survival. Interestingly enough and as opposed to some prior reports, the combination of weekly cisplatin and radiation actually proved to be superior with respect to both local-regional control and survival while providing a regimen that was fairly well-tolerated and in the aggregate actually had a lower toxicity rate than the every 3 week cisplatin, suggesting that at least at 40 mg per meter squared, we may have a regimen that is in the post-operative setting more efficacious, and better tolerated, and that it may be time to revisit standards of care or at least to perhaps accept 2 different standards of care in the post-operative setting; one being high dose every 3 weeks cisplatin and the other being weekly cisplatin. The other relevant abstract from the oral session was another randomized trial, this time from South Korea. Looking at adenoid cystic carcinoma, here patients were randomized to either receive a vascular endothelial growth factor receptor inhibitor named axitinib vs. placebo in patients with metastatic disease. This class of agents that axitinib belongs to has been noted to be active in adenoid cystic carcinoma for some time, but there had never really been any randomized trials comparing axitinib to any treatment and certainly not to observation or placebo. Fifty-seven (57) patients were enrolled and progression-free survival was the primary endpoint, in fact, 6-month progression-free survival. And what the investigators found was that this was much better in the axitinib patients versus placebo. In fact, about 70% of patients in the axitinib arm failed to progress and were still alive versus only 23% in the placebo arm. Now, this was not a large enough trial to change registration or the label of the drug, but it certainly, for patients with adenoid cystic carcinoma who have very few treatment options, does provide a therapy that now is at the very least validated through a randomized phase II trial and gives us a little bit more confidence in using this entire class of agents in patients with adenoid cystic carcinoma. One of the other targeted therapy studies that I think is also worth highlighting from the meeting was that using tipifarnib in patients with HRAS mutations. This was a study conducted across several different cancer types, but the most commonly enrolled patients and, in fact, a specific cohort were for patients with head/neck squamous cell carcinoma. And interestingly enough, the investigators having enrolled 18 patients found an overall response rate of 56%, arguably much better than we would be able to do with chemotherapy in these patients or any other targeted agent for that matter. And again, not a study that would change the label or standards of care but certainly worthwhile watching the efficacy of this agent tipifarnib going forward in patients with HRAS mutations. And then from the poster discussion session, I think we saw some interesting data that may be a prelude to the future, especially with immunotherapy. Christine Chung presented the experience of cetuximab and nivolumab, an EGFR and a PD-1 antibody in combination, and found that to be quite active, again, in a non-randomized manner but certainly enough activity to think about taking that regimen forward. Dr. Roger Cohen presented the monalizumab and cetuximab data in patients with recurrent or metastatic disease in this time in a cohort that were both platinum and PD-1 refractory, so a heavily pre-treated patient population, and very nicely finding a response rate of 20% in patients with squamous cell carcinoma in the head/neck. And then lastly, along the lines of immunotherapy, an update on the data within ICOS agonist GSK3359609 in combination with pembrolizumab in patients who were treatment naïve with head and neck squamous cell carcinoma or at least PD-1 treatment naïve and again finding some promising activity with a response rate of about 24%. The latter 2 trials, the monalizumab-cetuximab and the ICOS agonist pembrolizumab studies, are in fact now moving on to Phase III studies. And so again, there may be a change in the standard of care using some novel I-O regimens, and it's something to look out for in the future. Thank you for listening to this review of head and neck cancer abstracts at the American Society of Clinical Oncology Annual Meeting and have a nice day. ASCO: Thank you, Dr. Cohen. Next, Dr. Ryan Sullivan will discuss several studies across the field of melanoma treatment. Dr. Sullivan is a medical oncologist and Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital. He is also the Cancer.Net Associate Editor for Melanoma and Skin Cancer. View Dr. Sullivan’s disclosures at Cancer.Net. Dr. Sullivan: My name is Dr. Ryan Sullivan. I am the associate director of the melanoma program at Massachusetts General Hospital in Boston, and I'm here today to give a summary of some exciting data that was presented at the 2020 Annual ASCO Meeting which, of course, was presented virtually. I have a few disclosures, including that I have served on advisory boards for a number of companies whose data was presented, including Bristol Myers Squibb, Merck, Novartis, and Iovance. I'd like to start, really, by thinking about how a patient's journey with melanoma begins and then moves on through various stages of treatment, because there were a number of very interesting abstracts and presentations presented this year that include important breakthroughs in many different steps in the patient's journey. The first, of course, is a diagnosis, and soon after a diagnosis, often, the next step is surgery. There's been more and more data about treatment before surgery as a way of potentially improving outcomes for patients who have a significant amount of tumor in place, typically in lymph nodes. Treatment before a planned surgery is called neoadjuvant therapy. There's also been breakthroughs, and, at this year's ASCO, updates on these breakthroughs in treatment after surgery, which is done with curative intent. We call that type of treatment adjuvant therapy. There were some updates to studies in patients who have newly diagnosed metastatic disease, and then there were some very interesting presentations about data of patients who were treated after the first type of treatment, for a patient with metastatic disease, was ineffective, demonstrating some really promising second and even third lines of treatment that may be available for patients. So I'll start with that neoadjuvant therapy. This is, again, treatment that's given before somebody who could have surgery with curative intent, and the idea behind this is to potentially improve the outcomes of patients. It's also a really important type of research treatment because we can learn a ton about how tumors respond or don't respond to certain types of treatments, and there is a really wide path that's been created by the breast cancer community, who pioneered this type of treatment, and demonstrated that new and effective therapies can actually make it to the standard of care for patients in this setting. In melanoma, we've looked at a lot of the breakthrough therapies that have been approved in the metastatic and the stage 3 after surgery setting, including immunotherapies and BRAF-targeted therapies. And the background is a number of trials have occurred, and 1 very prominent group that has been leading a lot of these efforts is the group in the Netherlands, and Dr. Christian Blank presented some data on a follow-up study of almost 100 patients, who received a combination of two drugs, ipilimumab and nivolumab, at a schedule in dosing level that had been determined to be, probably, as effective as higher doses and more toxic therapy, but had a better safety profile than other regimens. That trial was called the OpACIN-neo, which randomized patients to 3 different dosing levels and strategies. So patients receive this, and then, in a really cool fashion, they knew that almost 70 or 80% of patients would have a major response to therapy - that was based on other data - but they also wanted to see if they get away with less surgery. And so what they did was, patients who had major responses were offered a smaller surgical resection. Patients who didn't have major responses ended up having a complete surgical resection of lymph nodes, and then they just followed along. And really, it was less a trial that will prove that this is the right thing to do, but more a trial to be built upon. And as more and more data comes out, this could be a strategy that we utilize for patients, where they may only get 2 doses of a treatment, and then if they have a major response to therapy, they could just be followed closely thereafter. So this trial is called the PRADO trial. Christian Blank was the presenter, and I would say it's promising, and maybe practice-changing as more data comes out and larger trials are performed to compare this strategy with other more standard strategies. The next set of data that was presented that's really interesting is in the adjuvant setting, so again, these are patients who've had surgery to cure them of their melanoma, but they're at high risk of the melanoma coming back and so receive treatment after surgery - we call that adjuvant therapy - to reduce the chance of disease coming back. There were 2 trials that were updated at this year's ASCO. One was the KEYNOTE-054 trial. This is randomizing a drug called pembrolizumab, an anti-PD-1 blocking drug, versus placebo. This trial was a positive study, and was published a few years back, and pembrolizumab was FDA approved, a few years back, for patients who have high-risk stage 3 melanoma, who have completed surgery. The follow-up data continues to show the superiority of the pembrolizumab compared to patients who received placebo, and importantly, that superiority is across virtually every subgroup that was analyzed, and demonstrates that this approach continues to be a standard approach for patients with melanoma who are high risk and have stage 3 disease that's been resected. A similar group of patients were enrolled on to a trial called the COMBI-D study. This is a trial that randomized BRAF mutated patients with stage 3 melanoma, whose disease had been removed, and received either dabrafenib and trametinib, which is a BRAF and MEK inhibitor, or 2 placebos. Again, this trial previously read out as a "positive study,” and this regimen has been FDA approved for this patient population. Importantly, the data continues to look really good. BRAF targeted therapy, initially, it was thought that it might prevent relapse during the treatment time and a little after the treatment time, but there was thoughts that the effects of it, and the effectiveness of it, might actually wane over time, but that doesn't seem to be the case. This is a 5-year update, and it still appears that this combination is associated with cures in patients with stage 3 melanoma, who would not have been cured if they didn't receive it. So again, really important follow-up data, and strengthens the idea that this is a very reasonable alternative to anti-PD-1 antibody therapy like pembrolizumab, which was described just a few minutes before, in the same setting, but in this case in patients who had BRAF mutated melanoma. There were some important trials, and one was a retrospective study of therapy in patients who had metastatic melanoma or unresectable disease, so this is melanoma that either presented in a widespread fashion, or was previously diagnosed and treated with surgery, maybe adjuvant therapy, and then metastasized. The standard front-line therapy is really 1 of 4 options: anti-PD-1 antibody with either nivolumab or pembrolizumab; BRAF targeted therapy, if a patient has a BRAF mutation; combination nivolumab and ipilimumab; and then enrollment onto a clinical trial. Many sets of data are out there in publications about the combination of ipilimumab and nivolumab in the frontline metastatic setting, and while it is associated with the highest response rates of immunotherapy in patients with melanoma, it's also associated with very high toxicity rates. And so ultimately, a decision is typically made upfront, and we balance the risk of the toxicities with the benefit of the therapy, and a decision is made about what to give. If a patient receives ipilimumab and nivolumab in the frontline setting, and then their tumor progresses thereafter, there aren't great second-line options unless a patient has a BRAF mutation, and then BRAF targeted therapy with 1 of the 3 BRAF/MEK combinations is an option. Patients who receive single-agent PD-1 therapy second-line treatment after disease progression-- could be single-agent ipilimumab, which was the first of these new immunotherapies to be approved. And so one of the questions, though, has been could you give combination ipilimumab plus a PD-1 blocking drug in that second-line setting, and have better outcomes than if you just gave ipilimumab? There's no randomized trial looking at this, but a group in Australia did a retrospective analysis and identified patients who received either single-agent ipilimumab, or a combination ipilimumab plus a PD-1 blocking drug. I should say that I was part of this retrospective analysis, and some of our patient data was part of this analysis. What was shown was that there were improvements in the response rate for patients who received combination ipilimumab plus a PD-1 blocking drug, versus single-agent ipilimumab, and it appeared that the benefit was about twice as good, meaning the response rate was about twice as good, and patients had about twice as solid progression-free survival, and they lived twice as long. Now, any retrospective analysis is really hard to make practice-changing decisions on, we really like randomized trials that are prospective, and so that data doesn't exist. There is a randomized prospective trial currently enrolling patients in the U.S. Cooperative Group setting, and it's randomizing patients, after PD-1 blocking drugs, to either ipilimumab or a combination of ipilimumab and nivolumab. So until that trial reads out, we won't know for sure that this is the right strategy, but the data certainly was suggestive that combination ipilimumab plus the PD-1 blocking drug makes sense. There actually also was data presented in a prospective study, 1 arm, so it wasn't randomized, that patients who'd been on a PD-1 blocking drug and then switched to pembrolizumab, a PD-1 blocking drug, and a low dose of ipilimumab after their disease had progressed on the PD-1 blocking drug. In that study, response rates were in the mid-20% range - I believe it was 27% - which is higher than we've seen with ipilimumab in that setting, for which the response rate would be expected to be about 10-15%. And so again, further data this time, prospective data, suggesting that there is an improved outcome for combination therapy in the second line. Importantly, toxicity, which we worry a ton about in the frontline, seemed to be less of an issue in the second line because we'd be comparing against ipilimumab, which is more toxic as a single agent than anti-PD-1 blocking drugs is, and in the second line, it seemed like combination therapy didn't seem to be any more toxic than single-agent ipilimumab. I think we also need to see the randomized data to firmly change the standard of care forever, but I think since this is a regimen that can be offered as standard care, with commercial product, it's an option for patients, and there's now data that really supports its use. The last study I'm going to talk about is a trial of a cellular product called lifileucel. In the '80s and '90s, in the National Cancer Institute, work led by Dr. Rosenberg and his colleagues, in the surgical branch there, developed the technique where they would remove a tumor, take out the T cells from the tumor, grow the T cells, expand them, and then give them back to patients after lymphodepleting chemotherapy, which would allow patients to receive and not destroy those T cells that were coming in, and then give IL-2 to grow those T cells and support them as they expand in the body. This is a very hard therapy to receive. At the NCI, it required patients to have an initial visit, have enough tumor to have it removed, be able to come back a few weeks later, have the tumor removed, and then the T cells had to grow, and we never really knew how many patients ended up showing up at the NCI to be evaluated for this, and then, ultimately, were treated. And so it is hard to know what to make of the response rates, which were remarkably high. As high as 50-55% in some studies when looking at the data. But the worry was that maybe only a quarter of patients that showed up ended up getting treated, and so the response rate would be a lot less, of all people that were screened. And so there's real interest in finding a commercial product that could not necessarily require the production of the cell product to be done at an individual institution, and certainly not 1 institution like the NCI, but that could be done centrally and commercially. And so lifileucel is a product that comes from patients’ tumors, again, requires a patient to have surgery, the tumor gets removed; it gets sent to a central laboratory where the T cells are isolated, grown, expanded; and then when the product is ready, patients, if they're still well, are able to be admitted to the hospital get lymphodepleting chemotherapy, receive the cells, receive IL-2, and then see what happens. The data that was presented at ASCO was an update from a year ago, which showed that patients-- and all of these patients had had anti-PD-1 antibody therapy, probably 70 or 75% of patients had ipilimumab, so heavily pretreated population of patients, and the response rate of patients who were able to receive treatment was 37%. So that's not everybody, obviously, and that's not even half the patients, but that's a pretty impressive response rate, for patients who weren't previously responding to immunotherapy. There's a lot of excitement about this data, and more importantly, there was data that suggested that 82% of patients that showed up for surgery ended up getting treated. So we actually have a denominator of patients screened. Ninety-four (94%), 95% of patients were able-- a product was able to be made, so the concerns about whether or not this is for most patients that end up having surgery, the answer is they probably can make a product for just about everybody. This is probably the 1 presentation, in the oral abstract session at ASCO, in the melanoma program, that is a regimen that would be new, and potentially practice-changing in the near future. So that's exciting, and we're hopeful that that will be an option for patients in the near future. With that, I'd like to finish by saying it was another great year for the melanoma research community. Lots of really interesting data presented. I touched upon some of the highlights, but lots of other really cool trials and data presented, as well, and I remain very hopeful for the future of, not just our research community, but more importantly for our patients, who are going to benefit from this wonderful research that's being done, which will hopefully continue to lead to better outcomes for our patients. And with that, I thank you for your attention. ASCO: Thank you, Dr. Sullivan. Learn more about the research presented at the ASCO20 Virtual Scientific Program at www.cancer.net/blog, and subscribe to Cancer.Net podcasts on Apple Podcasts or Google Play for additional episodes in the Research Round Up series, released throughout the summer. This Cancer.Net podcast is part of the ASCO Podcast Network. This collection of 9 programs offers insight into the world of cancer care, covering a range of educational, inspirational, and scientific content. You can find all 9 shows, including this one, at podcast.asco.org. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/donate.

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

Ezra Cohen, MD and Jyoti Mayadev, MD of the Moores Cancer Center demystify immunotherapy and explain how their research is applied to medical, surgical, and radiation oncology. Series: "UC San Diego Health Talks" [Health and Medicine] [Show ID: 36152]

La primera línea de defensa que usan nuestros cuerpos para combatir a los invasores extranjeros es nuestro asesino natural - o células NK. Dan Kaufman de la UC San Diego está utilizando nuevas tecnologías regenerativas con células madre pluripotentes inducidas para crear células NK utilizadas por Sandip Patel de Fate Therapeutics y Moores Cancer Center en un primer ensayo clínico en los Estados Unidos que usa células madre pluripotentes inducidas como tratamiento para destruir células cancerosas de tumores específicos. Series: "El Canal de Células Madre" [Spanish Language] [Show ID: 35157]

A primeira linha de defesa que nosso corpo usa para combater invasores são nossos matadores naturais – ou células matadoras naturas [células MN). Dan Kaufman, da UC em San Diego está utilizando novas tecnologias regenerativas com células-tronco pluripotentes induzidas para criar células MN usadas por Sandip Patel da Fate Therapeutics e Moores Cancer Center em um primeiro ensaio clínico americano usando células-tronco pluripotentes induzidas como um tratamento para destruir tumores cancerígenos específicos. Series: "O Canal de Células-Tronco" [Spanish Language] [Show ID: 35158]

A primeira linha de defesa que nosso corpo usa para combater invasores são nossos matadores naturais – ou células matadoras naturas [células MN). Dan Kaufman, da UC em San Diego está utilizando novas tecnologias regenerativas com células-tronco pluripotentes induzidas para criar células MN usadas por Sandip Patel da Fate Therapeutics e Moores Cancer Center em um primeiro ensaio clínico americano usando células-tronco pluripotentes induzidas como um tratamento para destruir tumores cancerígenos específicos. Series: "O Canal de Células-Tronco" [Spanish Language] [Show ID: 35158]

Lisa Madlensky, PhD, director of the Family Cancer Genetics Program at Moores Cancer Center at UC San Diego Health, explains the difference between medical grade DNA tests and consumer genetic... A podcast about science and discovery at UC San Diego Health. In each episode, we bring you the story of one project, one discovery or one scientist.

Anne Marbarger is the Executive Director of Padres Pedal the Cause. She joined me to talk about this organization that has raised just over ten million dollars in the last six years to fund research at four local cancer centers - The Moores Cancer Center, Sanford Burnham Prebys, The Salk Institute and Rady's Childrens Hospital. Each of the 53 grants they have funded includes a clinician on one side and a basic researcher on another to encourage collaboration among the four organizations. They have also funded some clinical trials. The intent is to fund high risk, high reward investigations that can then be further funded by larger granting agencies. The funds are raised through a one-day cycling, walking or spinning event that ends up on the field in Petco Park. You can participate as an individual or as a member of a corporate team. Listen to this episode to hear inspiring stories of people impacted by the event and learn how you and your company can participate. https://www.gopedal.org/ We are grateful for our sponsor:  Precision Medicine Leaders' Summit. It takes place Oct 10-11 in Torrey Pines. Use the code SAVE20 to save 20% on your ticket. Learn more about the podcast and advertising opportunities at sdbn.org/buzz  Subscribe on Apple Podcasts  Subscribe on Stitcher

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. The 2019 ASCO Annual Meeting, held May 31 to June 4, brought together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatment and patient care. In the annual Research Round Up podcast series, Cancer.Net Associate Editors share their thoughts on the most exciting scientific research to come out of this year’s ASCO Annual Meeting and what it means for patients. First, Dr. Lynn Henry will discuss 3 studies that explored new treatment options for women with breast cancer, including a study on immunotherapy for triple-negative breast cancer and 2 studies on treatment for hormone receptor positive, HER2-negative breast cancer. She also discusses research on the effects of a low-fat diet in women diagnosed with breast cancer, and a study on whether pregnancy after breast cancer increased the risk of recurrence.   Dr. Henry is an Associate Professor and Interim Division Chief of Oncology in the Department of Medicine at the University of Utah and Director of Breast Medical Oncology at the Huntsman Cancer Institute. She is also the Cancer.Net Associate Editor for Breast Cancer. Dr. Henry: Hi. My name is Dr. Lynn Henry. I'm a medical oncologist who specializes in treating breast cancer at the University of Utah. Today, I'm going to discuss research on breast cancer that was presented at the 2019 ASCO Annual Meeting in Chicago. In particular, I'm going to focus on the results of some clinical trials that directly impact how oncologists treat patients with breast cancer. First, I'm going to give just a very brief overview of the types of breast cancer and then talk about some research that was presented on triple-negative and hormone-receptor-positive breast cancer. Then I'm going to briefly review findings related to diet and breast cancer as well as pregnancy after breast cancer in women with BRCA mutations. As a quick reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone-receptor positive or estrogen-receptor positive, and those are stimulated to grow by estrogen. We treat those cancers with anti-estrogen treatments or anti-hormone treatments to block estrogen or lower the estrogen level in the body. Other breast cancers are called HER2-positive. These are often more aggressive cancers. But because they have extra copies of HER2, they often respond to treatments that block HER2. And finally, there are breast cancers that don't have hormone receptors or HER2, and these are called triple-negative breast cancer. So first, I'm going to focus on this type, triple-negative breast cancer. Until recently, most of the time, we treated triple-negative breast cancer with chemotherapy because we hadn't found other drugs that worked very well. There's a new type of drug, however, called immunotherapy that tries to use a patient's immune system to help fight the breast cancer. Early in 2019, the FDA approved a new treatment for triple-negative breast cancer that is a combination of a chemotherapy called Abraxane and a new immune drug called atezolizumab or Tecentriq. The combination increased the length of time until cancer progressed or grew. Overall, the treatment was fairly well tolerated. But we did learn that in order for the treatment to work, the cells surrounding the cancer have to have at least a small amount of a very specific protein called PD-L1. So at this recent ASCO meeting, we heard an update about this treatment. In the trial, the patients whose cancers had the PD-L1 protein and who got the combination treatment lived 7 months longer than those who got just the chemotherapy, which was an increase from 18 months to just over 2 years. This is an important first step towards finding a better treatment for this difficult type of triple-negative breast cancer. And this treatment is currently available to patients. Additional clinical trials are going on now to try to find even better combinations of chemotherapy and immune therapies to treat this type of cancer. So next, I'm going to talk about hormone-receptor-positive breast cancer. There were two trials of this type of cancer that had important results presented at the ASCO meeting. First, I'll focus on the treatment of early-stage node-negative breast cancer that is hormone-receptor positive and HER2 negative. The Oncotype DX test is a test we commonly run on tumors of this type to help determine whether treatment with chemotherapy is likely to be helpful. For this test, if your tumor has a score over 25, then chemotherapy is generally recommended in addition to anti-hormone therapy. If you have a score under 11, then chemotherapy is not recommended and a patient should receive only anti-hormone therapy. But for those with scores between 11 and 25, it was unclear how beneficial it was to receive chemotherapy. Last year, the results of the TAILORx trial were reported. And that showed that for women over the age of 50, if their tumor had a score between 11 and 25, they were not likely to get benefit from chemotherapy. However, it turned out it was a bit more complicated for women aged 50 and under. For those with scores between 11 and 15, chemotherapy was not likely to be beneficial. However, for those who score 16 to 25, chemotherapy might be beneficial. So we got some answers but not everything. At this recent ASCO meeting, additional information was reported to help guide treatment decision making for this middle group of women aged 50 and under. So for women whose scores were at the higher end, 21 to 25, chemotherapy was found to be likely to be beneficial. However, in that middle group, the 16 to 20 group, chemotherapy might be beneficial but generally only for women with higher risk cancers, meaning larger cancers or higher grade. This information is helpful because it provides more information for oncologists and for patients when they are discussing whether or not chemotherapy should be included as part of their treatment. So switching gears a little, still staying with premenopausal women and hormone-receptor-positive HER2-negative cancer, but now thinking about metastatic breast cancer, so cancer that has spread. We now have additional information about treatment with an anti-hormone therapy plus an additional drug called the CDK4/6 inhibitor. We've routinely been recommending this treatment combination because it leads to a longer time before the cancer progresses. But until now, we didn't know if it actually allows women with this type of cancer to live longer. The results of the MONALEESA-7 trial, which looked at the combination of an anti-hormone therapy plus the drug called ribociclib, showed that women who received the combination instead of anti-hormone therapy alone live almost 30% longer. So looking at women 3 and a half years after they started treatment, just over 70% of the women who were treated with ribociclib plus anti-hormone therapy were alive compared to just under half of women treated with anti-hormone therapy alone. So these results reinforce that this is an excellent first approach to treatment of premenopausal women who have newly diagnosed, hormone-receptor-positive HER2-negative metastatic breast cancer. So in addition to studies looking at these specific types of breast cancer, there were 2 other interesting studies that were applicable to breast cancer more generally. So there was a large study that was reported that looked at whether having a low-fat diet reduced the likelihood of developing triple-negative breast cancer. So in this study, postmenopausal without cancer were randomized to either a low-fat diet or their usual diet and followed for many, many years. Over time, some of these women developed breast cancer with no difference between those who followed the low-fat diet or the regular diet. However, in this new report, they looked specifically at the women who developed breast cancer who were enrolled in this trial. Fewer women died from their breast cancer if they ate the low-fat diet, especially if they had preexisting high cholesterol, diabetes, and obesity. These findings suggest that having a low-fat diet may actually reduce the risk of dying overall and also specifically from breast cancer. Now, these need to be validated, and we don't quite understand why this would be the case. But in general, it seems like having a low-fat diet, avoiding high cholesterol, diabetes, and obesity is a good thing. And then finally, 1 question that comes up often is whether it is safe to have a baby after the diagnosis of breast cancer. This is especially concerning for patients who have a mutation in genes called BRCA1 or BRCA2 since those mutations greatly increase their risk of developing both breast and ovarian cancer and also leads to the diagnosis of breast cancer at an early age. In addition, patients with these mutations are often recommended to have their ovaries removed at a young age. So in this study, patients who became pregnant did so about 4 and a half years after they were diagnosed with breast cancer. There was no apparent increase in miscarriage, preterm birth, or birth defects compared to what would be expected in women without cancer. And in the patients, there was no increase in the risk of breast cancer recurrence compared to those who did not become pregnant. And in fact, those who became pregnant were slightly less likely to have their cancer return, especially those who had mutations in BRCA1. So while there are some limitations to the study, the findings are reassuring that there does not appear to be an increase in risk of breast cancer returning in these patients with BRCA mutations who become pregnant after breast cancer diagnosis. So overall, as you can see, there's a lot of exciting research going on across all the different subsets of breast cancer. The results of many important clinical trials were reported at the recent ASCO meeting, and there are many more trials ongoing that will hopefully result in the approval of multiple new effective treatments for breast cancer. In addition, there's research going on examining the impact of treatment on patients with breast cancer and trying to improve the lives of those living with breast cancer. Clinical trials are critical for the development of these new treatments. Well, that's it for this quick summary of this important research from ASCO 2019. Overall, we continue on a fast track in breast cancer, with many new and exciting therapies being actively studied and research helping support our patients do better than ever before. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you very much. ASCO: Thank you, Dr. Henry. Next, Dr. Ezra Cohen will discuss several studies that looked at using immunotherapy and targeted therapy to treat different types of head and neck cancer. Dr. Cohen is Associate Director of Translational Science and leads the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. He is the Cancer.Net Associate Editor for Head and Neck Cancer. Dr. Cohen: Hi. I'm Dr. Ezra Cohen from UC San Diego Moores Cancer Center. Today, I'm going to talk about research on head and neck cancer that was presented at the 2019 ASCO Annual Meeting. I think the most impactful presentation at the meeting was a follow-up on the KEYNOTE-048 study, which implemented the drug pembrolizumab, an anti-PD-1 antibody in first-line recurrent metastatic head and neck cancer. These were patients who were treated with curative intent or presented with metastatic disease, and either way, either had recurrence or eventually developed metastases. The first-line standard of care for these patients used to be the so-called extreme regimen, which involved platinum, 5-FU, and cetuximab. This was validated in an earlier phase III study that was conducted about 10 years ago and was the approved first-line regimen for these patients. In KEYNOTE-048, this extreme regimen was tested against either pembrolizumab alone or pembrolizumab, platinum, and 5-FU, in other words, substituting cetuximab for pembrolizumab in one of the experimental arms. We'd initially seen the interim analysis data at last year's ESMO meeting, but this year, we have the final analysis presented at ASCO. And what we saw was that both experimental arms actually achieved an improvement in overall survival compared to the extreme regimen. Interestingly, for pembrolizumab alone, this occurred in patients whose tumors expressed some level of PD-L1. That was evaluated by something called the composite score and takes into account both stromal and tumor cell staining of PD-L1. In fact, even at a very low level—that is CPS greater than or equal to 1—pembrolizumab monotherapy was superior to the extreme regimen with respect to overall survival. For all patients, the regimen of pembrolizumab plus chemotherapy was superior to the extreme regimen irrespective of PD-L1 staining. What we saw at this year's ASCO meeting was that, in fact, first, the higher the expression of PD-L1, the greater the benefit one derived from pembrolizumab either as monotherapy or in combination with chemotherapy. And in patients who had higher levels of PD-L1 and received both pembrolizumab and chemotherapy, the overall survival was quite remarkable with a hazard ratio of just higher than 0.6. In fact, we now have FDA approval in the United States for pembrolizumab monotherapy with tumors that have some expression level of PD-L1—that is CPS greater than or equal to one—or for all comers in patients who either the CPS status is unknown or patients whose tumors don't express PD-L1. Beyond KEYNOTE-048, we saw interesting data in first-line recurrent metastatic using a regimen of taxane, platinum, and 5-FU compared to the same extreme regimen that we just mentioned. That regimen turned out to be much better tolerated with fewer adverse events but with no improvement in overall survival, giving us a regimen that we could substitute for the extreme regimen if one wanted to, realizing that it does not involve immunotherapy, and for some patients, this may still be an appropriate treatment. Beyond the first-line recurrent metastatic studies, we saw a few interesting trials looking at targeted therapy in head and neck cancer but specific subsets. The first was in patients whose tumors expressed HER2 at very high levels—that is HER2 amplified—and had salivary ductal carcinoma. We've known that a proportion of salivary ductal carcinoma patients' tumors amplify this gene, HER2, similar to breast cancer and some other malignancies and that trastuzumab may, in fact, be effective. Well, in this study conducted by the Memorial Sloan Kettering Group, an antibody-drug conjugate trastuzumab emtansine was employed as a single agent in these patients whose, again, tumors amplified HER2. And what they saw was a remarkable 90% response rate. Now, this was only in 10 patients, so the study is small, but I think it's safe to say that this drug appears to be quite effective in patients with HER2-amplified salivary ductal carcinoma. Along those lines, in the subset of thyroid cancer patients whose tumors either mutate or have a RET fusion, the gene RET, there appeared to be very high efficacy for a novel agent that targets the RET oncogene. This was in both patients with medullary thyroid cancers that often have a RET mutation or in papillary thyroid cancers whose tumors often have a fusion of the same RET gene. Again, underscoring the idea that if we can target a driver even in a relatively small subset of patients, the benefit may be quite large. Along those lines, we had seen prior data for track inhibitors in patients who have in track fusions. And again, this applies to subsets of head and neck cancer patients that have either salivary gland cancers or thyroid cancers. Lastly, we continue to see emerging promising data of combinations with immunotherapy, and 2 highlights from ASCO were pembrolizumab with cetuximab showing a response rate of over 40% in a small group of patients and pembrolizumab with a TLR9 agonist called SD-101 showing about a 30% response rate. Of course, these data are very early and uncontrolled, and so we have to follow these stories further along to see if, indeed, these early signs of efficacy turn out to validate. But the idea that further combinations of immunotherapies eventually making their way to larger studies and hopefully approval is now well enforced in head and neck cancer. Thank you very much for your attention and hope you enjoyed the ASCO 2019 Annual Meeting. ASCO: Thank you Dr. Cohen. Next, Dr. Charles Loprinzi will discuss new research on ways to prevent or treat nausea and vomiting caused by cancer treatment. Dr. Loprinzi is a medical oncologist and the Regis Professor of Breast Cancer Research at the Mayo Clinic. He is also the Cancer.Net Associate Editor for Psychosocial Oncology. Dr. Loprinzi: Hello, I'm Charles Loprinzi, Regis Professor of Breast Cancer Research at Mayo Clinic. I'm going to be talking today about chemotherapy-induced nausea and vomiting. Now, chemotherapy can cause a lot of nausea and vomiting. That's well known, for years and years, by many people. It's not all types of chemotherapy, but some chemotherapy drugs cause a lot of nausea and vomiting, and others cause little to none. It's not as big a problem now as it was decades ago when we didn't have good drugs to try to prevent nausea and vomiting. Many drugs over the time have been developed for trying to prevent this nausea and vomiting problem. Examples of the drugs that cause a lot of nausea and vomiting are Cisplatinum, and Adriamycin and cyclophosphamide is a combination that is oftentimes used for patients with breast cancer. So in the past, we have developed many, many drugs for this. Three of the drugs that have commonly been used for the last many, many years for treatment or prevention of nausea and vomiting associated with chemotherapy are corticosteroid medications like Dexamethasone. It's quite cheap. It's got some side effects, but relatively cheap. Then there's a group called 5-HT3 receptor antagonists. I didn't make up that name, but that's the long name for it. They're relatively expensive, some more expensive than other ones. And then there's another group called NK1 receptor antagonists, and they can be quite expensive, sometimes being hundreds of dollars for each dose that's given to try to prevent nausea and vomiting related to chemotherapy. So a couple years ago, 2016, there was a report in the New England Journal of Medicine, which is a prominent journal for us in the business, that looked at a drug called olanzapine. It's a relatively cheap drug. It's a drug that was developed for psychosis-type problems, given for long term in those patients. But it had been noted that if it's given for just a few days, it seems to markedly improve or decrease the instance of nausea and vomiting, or if people were having nausea and vomiting, it appears actually to help and reverse that particular problem. So this trial looked at 10 milligrams of this drug for 4 days, given before chemotherapy, and then for 3 more days after that. Patients who were on this study got the 3 drugs that I talked about before with the olanzapine or with the placebo. And it noted that it improved things by quite a bit. The patients who had what we call a complete response, which means no vomiting and no need to take extra medications because of nausea and vomiting, improved from 41% of the patients who were on the placebo, to 64% who were on the olanzapine, a 23% improvement. And if we looked at a different endpoint there, the number of patients who had no nausea during the five days after chemotherapy, it was 22% in the group that got the placebo and improved to 37% in the group that didn't. So it was a good result in that area. One of the problems with this drug is that it can cause some sedation, cause some drowsiness for some patients. Most patients, not much, but some patients, it's a problem. So most trials that have been done in the past use this 10-milligram dose. And what we learned at ASCO in 2019, our main meeting that we have once a year, was that people looked at a 5-milligram dose and had looked at 5 milligrams instead of the 10 milligrams. And what it showed is that the results seemed to be quite similar to what was seen with 10 milligrams. They did the study quite the same as what had been reported in the previous trial and the results looks similar. They didn't compare 5 milligrams versus 10 milligrams, which would've been nice because then we would have better information along that line. They did note that there was drowsiness that some patients had, and it looks similar to what was seen with the 10-milligram dose. But these data support, but don't prove, that giving 5 milligrams does look like it's good in this particular setting. So data from this year also supported that instead of giving the drug during the day when getting the chemotherapy, sometimes, people take it at bedtime, and there, the drowsiness is not as big a problem because you want to be drowsy at bedtime. So it's not proven that it works as well at bedtime, but it suggests that that actually is the case. Data from this year also supported that if you looked at those 3 drugs I mentioned before and just took out that 1 really, really expensive one, the NK1 receptor antagonist, and put the olanzapine in there instead, that very cheap medication, that that looked like that one with the olanzapine did better than the very expensive one. Not a whole lot better; they looked similar, but a little bit better in that setting, and it was a whole lot cheaper. This was also seen in a publication that came out a couple of years ago which showed the same sort of result. Again, not proof that it's beneficial, that it's okay to do that, but it looked better. So the next obvious question that comes up then is when you have these 4 drugs that you give, the 3 drugs I mentioned before and this fourth one, what about if you take away that more expensive one and see how they do there? So there was a trial at the ASCO meeting that suggested that the addition of that expensive medications didn't provide a whole lot more benefit. Right now, there is a trial going on across the United States, with about 800 patients who are scheduled to go on this trial, and it's approving about 30 patients a month, which is a pretty good accrual rate, which is looking at this particular question where people would get the 4-drug regimen versus 3 drugs where they take away the expensive intravenous medication. So, in summary, 35 to 40 years ago, when I started my cancer career, when I was about 10 years old, most patients had a lot a trouble with nausea and vomiting with drugs like Cisplatinum. Now, this a minority of patients who have a lot of problems, and we're continuing to find new things that will make things better along this line. Thank you for your attention. ASCO: Thank you Dr. Loprinzi. Learn more about these topics and other research presented at the 2019 ASCO Annual Meeting at www.cancer.net. If this podcast was useful, please take a minute to subscribe, rate, and review the show on Apple Podcasts or Google Play. And stay tuned for additional Research Round Up podcasts coming later this summer. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/support.

Tamara Strauss, the first patient to enroll in a first-of-its-kind clinical trial at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to... A podcast about science and discovery at UC San Diego Health. In each episode, we bring you the story of one project, one discovery or one scientist.

Diet and Exercise Advice while undergoing Cancer Treatments with Dr. J. Kellogg Parsons. Dr. Parsons is a board-certified urologist who specializes in diagnosing and treating prostate cancer. He directs clinical trials for the Department of Urology at UC San Diego Health's Moores Cancer Center.

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD's Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Food is medicine. That insight inspired the late rancher and developer Dick Krupp to endow one of the largest funds of its kind to support integrative nutrition research at UC San Diego. As Gordon Saxe, MD, the director of UCSD’s Center for Integrative Nutrition and others explain, the Krupp-funded projects focus on how diet and natural therapeutics can help reduce or cure common health problems. Among the projects featured – feeding cancer patients congee, a grain-based porridge to ease the side effects of chemotherapy, a study led by Caitlin Costello, MD, of the Moores Cancer Center. Also, Sanjay Agarwal, MD, looks at the impact of a healthy diet on women who suffer from endometriosis. And finally, Robert Weinreb, MD, the director of the Shiley Eye Institute, introduces a new field of medicine called Integrative Ophthalmology. All agree: what you eat matters! Series: "UCTV Prime" [Health and Medicine] [Show ID: 33133]

Ezra Cohen, MD, is a board-certified oncologist and cancer researcher. He cares for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers. Dr. Cohen is also an internationally recognized expert on novel cancer therapies and heads the Solid Tumor Therapeutics program at Moores Cancer Center. Much of his work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. As a physician-scientist, he is especially interested in developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). He was recently appointed chair of the National Cancer Institute Head and Neck Cancer Steering Committee, which oversees NCI-funded clinical research in this disease. Dr. Cohen is editor-in-chief of Oral Oncology, the most respected specialty journal in head and neck cancer. A frequent speaker at national and international meetings, he has authored more than 120 peer-reviewed papers and has been the principal investigator of multiple clinical trials of new drugs in all phases of development.  In this episode, topics include: Drug therapy for patients that fail standard therapy; including surgery and RAI Not all patients have same behavior for their cancer Some cancers are aggressive Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands What is the treatment protocol for therapy? Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer Lenvatinib tends to be more effective Sorafenib is tolerated by the patient better Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF BRAF inhibitors used with thyroid cancer patients Molecular profiling DNA sequencing Side effects include, what patient will feel and those that appear in blood tests Side effects include fatigue in 60% patients, hand or foot blisters, nausea and vomiting Side effects in blood tests include high blood pressure, increase in liver enzymes, and a reduction in blood counts VEGF receptor CT scans and ultra sounds or thyroglobulin as an indicator that thyroid cancer not responsive to traditional therapy We don’t want to make the patient feel worse; the question is when to treat the patient with drug therapy Drug treatment does no cure the disease Holidays from the drug and be rid of side effects When restarting drug, disease responds again Pediatric care Immunotherapy NOTES Ezra Cohen, MD American Thyroid Association  

Dr. Ezra Cohen, Professor Division of Hematology/Oncology Department of Medicine University of California San Diego and Associate Director for Translational Science at the UC San Diego Moores Cancer Center shines light on the newest innovations in immunotheraphy for treating cancer, using precise cellular therapies and check point inhibitors to reactivate the immune system to attack cancer cells, and the promise of being able to prevent cancer using personalized vaccines. @UCSDHealth UC San Diego Moores Cancer Center UC San Diego Health Services Presentation on Immuotheraphy

In this extra-long, extra personal episode, Heather talks to Rikki Rockett, drummer in the band Poison, on the day he was at Moores Cancer Center at UC San Diego Health for a scan that would tell him... A podcast about science and discovery at UC San Diego Health. In each episode, we bring you the story of one project, one discovery or one scientist.

Today's episode features Dr. Ruth Patterson, a professor in the UC San Diego Department of Family Medicine and Public Health as well as Associate Director of Population Sciences and leader of the Cancer Prevention program at Moores Cancer Center at UC San Diego Health. If you enjoyed my last episode with Dr. Satchin Panda, I have good news! This will also be a great episode for you, since we talk about some similar ideas, but focus more on the human side of things, especially when it comes to time-restricted eating, since Dr. Patterson does primarily clinical research. In this 45-minute podcast, we talk about... The importance of time-restricted eating as a practical public health intervention, mostly for it's ease of implementation, that may have a widespread impact on disease risk. Why you should probably make sure your time-restricted eating window occurs earlier in the day, rather than later. How the first 5% drop in weight loss can have disproportionately large effects on the metabolic factors associated with breast cancer risk when compared with subsequent weight loss. The association of longer fasting durations beginning earlier in the evening and improved sleep in humans, as well as spontaneous physical activity in their day-to-day lives. The relationship between metabolism and breast cancer risk. The effect of lifestyle factors, such as obesity, physical activity, what and even when you eat, whether or not you smoke tobacco... and how even modest changes, such as consuming food earlier in the day and only during an 11-hour window, can decrease breast cancer risk and recurrence by as much as 36%. The importance of starting your fast earlier in the evening, and how an earlier eating window has been shown to correlate to reductions in inflammatory markers. The association of higher circulating insulin levels with breast cancer risk, and how insulin itself has an important relationship with estrogen by affecting the levels of sex-hormone binding globulin. The dangers of having a cellular environment that is inflamed, as the case is with the obese, and simultaneously having elevated cellular growth signals, which is also characteristic of the hormonal milieu of the obese. The surprisingly small role heredity plays in determining overall risk of breast cancer when compared to lifestyle factors. How healthful lifestyle habits, like choosing to eat during the right window, ultimately helps us trend our risk for many of the diseases of old age in the correct direction instead of influencing only one or another. If the concept of time-restricted eating especially piques your interest, make sure to... Check out the podcast released just prior to this one: Dr. Satchin Panda on Time-Restricted Feeding and Its Effects on Obesity, Muscle Mass & Heart Health. Make sure your data points go to good use! Visit myCircadianClock.org to learn how you can, by committing to a minimum of a 14 week "intervention" and submitting pictures of your food from your iPhone or Android phone, move human research on time-restricted eating forward. Huge special thanks to Dr. Ruth Patterson for coming on. Enjoy the podcast!

Dr. Ruth Patterson Dr. Ruth Patterson, a professor in the UC San Diego Department of Family Medicine and Public Health as well as Associate Director of Population Sciences and leader of the Cancer Prevention program at Moores Cancer Center at UC San Diego Health. In this epsidode, we chat about: The importance of time-restricted eating as a practical public health intervention, mostly for it's ease of implementation, that may have a widespread impact on disease risk. Why you should probably make sure your time-restricted eating window occurs earlier in the day, rather than later. How the first 5% drop in weight loss can have disproportionately large effects on the metabolic factors associated with breast cancer risk when compared with subsequent weight loss. The association of longer fasting durations beginning earlier in the evening and improved sleep in humans, as well as spontaneous physical activity in their day-to-day lives. The relationship between metabolism and breast cancer risk. The effect of lifestyle factors, such as obesity, physical activity, what and even when you eat, whether or not you smoke tobacco... and how even modest changes, such as consuming food earlier in the day and only during an 11-hour window, can decrease breast cancer risk and recurrence by as much as 36%. The importance of starting your fast earlier in the evening, and how an earlier eating window has been shown to correlate to reductions in inflammatory markers. The association of higher circulating insulin levels with breast cancer risk, and how insulin itself has an important relationship with estrogen by affecting the levels of sex-hormone binding globulin. The dangers of having a cellular environment that is inflamed, as the case is with the obese, and simultaneously having elevated cellular growth signals, which is also characteristic of the hormonal milieu of the obese. The surprisingly small role heredity plays in determining overall risk of breast cancer when compared to lifestyle factors. How healthful lifestyle habits, like choosing to eat during the right window, ultimately helps us trend our risk for many of the diseases of old age in the correct direction instead of influencing only one or another.   If you're interested in learning more, you can read the full show notes here: https://www.foundmyfitness.com/episodes/ruth-patterson Join over 300,000 people and get the latest distilled information straight to your inbox weekly: https://www.foundmyfitness.com/newsletter Become a FoundMyFitness premium member to get access to exclusive episodes, emails, live Q+A's with Rhonda and more: https://www.foundmyfitness.com/crowdsponsor

Women who are midnight snackers may want to listen up: a University of California, San Diego study has found that overnight fasting may reduce breast cancer risk. Catherine Marinac, a doctoral candidate at the Moores Cancer Center says their study measured women who fasted a little over twelve hours a night. "We found that in general, women who fasted for longer nighttime intervals had better blood- sugar control and the effects were independent of how many calories women ate, what their body composition was, their BMI, their age and other factors that we think might influence that association." While Marinac says larger studies are necessary, these findings do correlate with previous research with animal models – and the message she says, is a simple one. "We think that a long nighttime fasting interval is a simple, feasible and effective strategy that could reach broad populations of women."

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of AmericaRamez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA